1551 results about "Target drug" patented technology

A novel delivery system for targeting drugs to the colon is herein described. The system is a tablet comprised of three parts: 1) an outer enteric coating, 2) an inner semi-permeable polymer membrane containing a plasticizer and 3) a central core comprising swelling excipients and an active ingredient. The novel dosage form described herein will release the drug consistently in the colon by a time-dependent explosion mechanism. This delivery system is particularly suitable for delivering viral protease inhibitors to the colon.

A method and apparatus for reducing the workload of titrating drug to effect while leaving clinician users in control of a related procedure is described. A drug delivery device is controlled to achieve a target drug concentration at a selected site in the patient or a predetermined infusion rate waveform. The time profile of the target drug concentration or a predetermined infusion rate waveform is controlled by a drug state model that uses clinical heuristics to implement safe, pre-defined changes in the target drug concentration or infusion rate and user-commanded changes in target drug concentration or infusion rate. The invention allows time to assess the response of the patient to changes in drug level by making small incremental and conservative changes in drug level over time.

This invention relates to polymeric nanoparticles useful for drug delivery with target molecules bonded to the surface of the particles and having sizes of up to 1000 nm, preferably 1 nm to 400 nm, more preferably 1 nm to 200 nm, that are dispersed homogeneously in aqueous solution. The target drug / target substance is covalently bonded to the novel polymeric nanoparticles to secure them from outer intervention in vivo or cell culture in vitro until they are exposed at the target site within the cell. This invention also relates to microemulsion polymerization techniques useful for preparing the novel nanoparticles.

A composition comprising intact minicells that contain a drug molecule is useful for targeted drug delivery. One targeted drug delivery method employs bispecific ligands, comprising a first arm that carries specificity for a bacterially derived minicell surface structure and a second arm that carries specificity for a mammalian cell surface receptor, to target drug-loaded minicells to specific mammalian cells and to cause endocytosis of the minicells by the mammalian cells. Another drug delivery method exploits the natural ability of phagocytic mammalian cells to engulf minicells without the use of bispecific ligands.

The present invention provides a method of applying a drug-polymer coating on a stent. A stent framework is dipped into a first polymeric solution including a first polymer, a first therapeutic agent, and a first solvent. The polymeric solution is dried and the first polymer is cured to form a thin drug-polymer layer on the stent framework. The steps of dipping the stent framework into the first polymeric solution, drying the first polymeric solution, and curing the first polymer are repeated until a target drug-polymer coating thickness is disposed on the stent framework. A drug-polymer coated stent including a stent framework and a laminated drug-polymer coated stent, a system for treating a vascular condition, and a method of treating a vascular condition are also disclosed.

The invention relates to a preparation method of a hollow mesoporous silica nanoparticle. The preparation method comprises the following steps: obtaining a polymer-silica composite nanoparticle having a core-shell structure by adopting spherical aggregations of an amphiphilic segmented copolymer in an aqueous solution and a cationic surfactant hexadecyl trimethyl ammonium bromide as double templates and ethyl orthosilicate as a silicon source and by hydrolyzing the silicon source under an alkaline condition; and calcining to remove the templates to obtain the hollow mesoporous silica nanoparticle. The preparation method has the advantages of simplicity, mild reaction condition, and cheap experiment raw materials, and the prepared mesoporous silica nanoparticle has the advantages of high specific surface area, high pore volume, and good biological compatibility. The hollow structure enables the drug loading amount to be substantially improved, nanometer gold, nanometer silver, magnetic iron oxide particles, quantum dots, a contrast agent and the like to be loaded, so the hollow mesoporous silica nanoparticle can be used as a targeting drug release carrier, can be used for magnetic resonance image analysis, and has good application prospects in the fields of the diagnosis and the treatment of cancers.

The invention belongs to a transdermal delivery soluble microneedle patch, and especially relates to a soluble microneedle vaccine patch and a preparation method thereof. The soluble microneedle vaccine patch is composed of a soluble microneedle substrate containing no target drug, and a soluble microneedle body containing the target drug; the target drug of a vaccine and the adjuvant suitable for the vaccine is loaded at the front end of the soluble microneedle body, the vaccine and the adjuvant suitable for the vaccine are loaded on nanoparticles, and the nanoparticles are uniformly distributed at the front end of the soluble microneedle body; and the matrix material of the soluble microneedle vaccine patch is a biocompatible water-soluble polymer material. The soluble microneedle body of the soluble microneedle vaccine patch suitable for vaccine transcutaneous immunization has enough hardness and can effectively penetrate the stratum corneum of skin surface, and the front end of the needle body entering the skin can realize fast dissolving and release of the target drug stored in the front end of the needle body.

The invention relates to a multifunctional double-layer core-shell structure magnetic nano particle. In the invention, a magnetic nano particle with a particle size of 1-300 nm is used as a core and coated with a double-layer shell consisting of a SiO2 layer with a thickness of 1-200 nm and a hydrolyzed silane coupling agent layer is 1-100 nm thick and comprises one or more multifunctional groups; the particle size and the shell layer thickness can be controlled through regulating the volumes, the weight ratios and the reaction time of the magnetic core, a silicon dioxide precursor, a silane coupling agent and a catalyst in a preparation process; the total particle size of the nano particle can be as small as 5-50 nm and as large as 700-800 nm; the nano particle can have superparamagnetism, paramagnetism and ferromagnetism according to the change of the magnetic core particle size; and one or more bioactive molecules can be connected into the shell layer of the magnetic nano particle or to the surface of the shell layer through a chemical method or a physical method. The invention also provides a preparation method of the multifunctional double-layer core-shell structure magnetic nano particle and application thereof. The particle preparation method has the advantages of simplicity, moderate condition, low cost and easy realization of industrial production. The nano particle can obtain different functions through connecting different bioactive molecules and can be applied to the fields of protein enrichment, biological detection, separation and purification, targeted drug carriers, cell imaging and medical imaging.

A computer-implemented apparatus or method, or a software product, for generating a composite quantitative comparison of drug products based on multiple attributes of them. A set of name-attribute similarity scores are generated based on similarities among the names of selected target and reference drugs. A set of product-attribute similarity scores are generated based on similarities among product attributes of the selected target and reference drugs. A target drug confusability score is generated based on the confusability of the target drug as compared to a population of other drugs. The composite quantitative comparison is generated based on a composite of the name-attribute and product-attribute similarity scores, and the target confusability score. A set of one or more severity of confusion scores may also be included in the composite quantitative comparison. These scores are based on one or more indicators of the severity of the consequences to a patient of confusing the target and reference drugs so that, for example, the wrong drug is administered to the patient, or the correct drug is incorrectly administered. The name-attribute similarity scores may be generated based on orthographic, phonetic, and / or phonological analysis. The product-attribute similarity scores may be generated based on the drugs'strengths, indications, dosages, administration routes, manufacturers, pharmacological categories, storage requirements, colors, shapes, legal standing, trademark description, and / or other attributes. The composite quantitative comparison may include severity-weighted similarity scores or both similarity scores and severity of confusion scores. The severity of confusion indicators may include a therapeutic index and / or a contraindication index.

The invention discloses a preparation method of magnetic / gold nano particles. The preparation method comprises the following steps: firstly adopting a co-precipitation method to prepare the magnetic Fe3O4 nano particles; polymerizing the dopamine in-situ on the surfaces of the magnetic particles to obtain Fe3O4 nano particles modified by the poly dopamine; introducing polyphenol and amino groups to the surfaces of the Fe3O4 nano particles; absorbing the nano gold seeds on the surfaces of the modified magnetic particles through the static action; adopting the nano gold which is absorbed on the surfaces of the magnetic particles as the seed, adopting the polyphenol on the surfaces of the magnetic particles as a reducing agent, gradually adding the chloroauric acid liquid to gradually produce the gold layers on the surfaces of the magnetic particles to obtain the core-shell magnetic / gold nano particles. The nano particles have good water dispersion and strong magnetic respond performance. The diameters of the nano particles are 30-100 nanometers, the saturation magnetization is 30.1-38.7emu / g, and the nano particles are superparamagnetic. The nano particles have wide application prospect on the fields of targeted drug controlled release, thermal therapy, separation of protein and enzyme, etc.

The invention discloses a next generation sequencing-based detection panel and detection kit for pan-cancer targeting, chemotherapy and immune drugs and application thereof. The detection panel includes gene mutations related to pan-cancer type, treatment and prognosis, tumor mutation load calculation related exon regions and microsatellite instability sites. According the technical solution of the present invention, the detection panel includes the gene mutations related to pan-cancer type, treatment and prognosis, the tumor mutation load calculation related exon regions and the microsatellite instability sites, and the gene information included is comprehensive; a variety of tumor mutations can be jointly detected; and the detection panel and detection kit can be used for the concomitantdiagnosis of targeted drugs, chemotherapeutics or immune drugs to obtain accurate results.

The invention relates to a novel liver target drug carrier-glycyrrhetinic acid-polyethylene glycol / chitosan or chitosan derivative liver target compound drug delivery system. During the preparation of the nano-drug delivery system, the liver target small-molecule glycyrrhetinic acid is firstly used for modifying amino polyethylene glycol by the different sites, then a water soluble big-molecule liver target compound is prepared and is mixed with a solution containing chitosan or chitosan derivative by a certain proportion, an ion cross-linking agent is added under the stirring condition, and a target group is introduced at the same time of the spontaneous formation of nanoparticles by physical winding and electrostatic interaction. The method of introducing the target group of the invention is novel, the formation of spheres is simple, the conditions are moderate, and the content of the target group is high (the weight percentage of glycyrrhetinic acid is 5 to 30 percent). The drug delivery system has strong killing capacity to the cancer cells, the in vitro experiments show that the drug delivery system has very strong binding capacity with the liver cells, and the high content of the target group can improve the liver target capacity of the drug delivery system, realize the target positioning of the liver and open a new way for the treatment of liver cancer.

The present invention provides a method of applying a drug-polymer coating on a stent. A stent framework is dipped into a first polymeric solution including a first polymer, a first therapeutic agent, and a first solvent. The polymeric solution is dried to form a thin drug-polymer layer on the stent framework. The stent framework with the thin drug-polymer layer, which is insoluble in the second polymeric solution, is dipped into a second polymeric solution including a second polymer and a second solvent and is dried to form a thin barrier layer on the thin drug-polymer layer. The steps of dipping the stent framework into the first polymeric solution, drying the first polymeric solution, dipping the stent framework into the second polymeric solution, and drying the second polymeric solution are repeated until a target drug-polymer coating thickness is disposed on the stent framework.

The invention provides methods, reagents and systems to preferentially mark fast-proliferating cells / tissues (such as cancer), by incorporating non-natural amino acids into proteins, preferably in vivo, using the endogenous protein synthesis machinery of an organism. The incorporated non-natural amino acids contain reactive groups for further chemical reagents, which may serve as a “handle” to for a number of uses, such as imaging of cancer cells, targeting drugs to preferentially kill cancer cells, and proteomic analysis in the context of large scale or high throughput screening for candidate drug leads that affects the proliferation of a target cell, etc.

Disclosed is a conjugate comprising a biologically active agent (drug) linked to a subcellular targeting moiety that targets a drug specifically to the nucleus. Targeting is achieved by attaching a steroid hormone (or an analog) to the drug. The steroid hormone attached to the drug binds its corresponding receptor, the formation of the receptor-ligand complex results in the internalization of the complex into the nucleus, thus resulting in nuclear translocation of the drug. Also disclosed is a conjugate (comprising the complex of the drug and the steroid hormone) bound to a polymer by spacers allowing for concurrent passive targeting to the tumor cell (afforded by attachment to the polymer by the EPR effect) and nuclear targeting of the conjugate (due to the presence of the steroid). Using a suitable degradable spacer allows for the release of free drug in the tumor and enhances nuclear targeting efficacy. The polymer can be further linked to a cellular targeting molecule, where the targeting molecule directs the polymer to specific cells. One may thus be able to effectively target drugs to the nucleus of tumor cells. With little or modifications, several therapeutic agents can be targeted using the invention.

The invention relates to a nanofiber membrane and particularly relates to a novel composite nanofiber membrane as well as a preparation method and application thereof. The preparation method comprises the following steps: (1) dissolving any one of polyvinyl alcohol, polylactic acid and regenerated silk fibroin in an organic solvent to prepare a spinning solution with the mass fraction of 5-20 percent; (2) adding polyphenol substances to the spinning solution, and uniformly stirring to obtain a mixed spinning solution which accounts for 1-7 percent of the total mass of the polyphenol substances and the organic solvent, wherein the polyphenol substances are one or more of vegetable tannin, apple polyphenol and grape polyphenol; (3) carrying out ultrasonic treatment on the mixed spinning solution for 1-600 minutes; and (4) carrying out electrostatic spinning on the mixed spinning solution and collecting to obtain the required composite nanofiber membrane. After subjected to electrostatic spinning, the composite nanofiber membrane is smooth in surface, continuous and uniform, has the diameter of between 100nm and 800nm and can be applied to the fields of medical dressing, makeup facial masks, tea bags, controlled release of targeted drugs, food preservation and sewage purification.

The invention discloses a drug repositioning method based on multi-information fusion and a random walk model. According to the method, disease-target-drug heterogeneous network is constructed through integrating existing disease data, drug data, target data, disease-drug associated data, disease-gene associated data and drug-target associated data; the basic random walk model is extended to the constructed heterogeneous network; and candidate therapeutic drugs are recommended for diseases through effectively utilizing global network information. The method disclosed by the invention is simple and effective; and compared with other methods and proved by tests on a standard data set, the method has good prediction performance in the aspect of drug repositioning.

Drug-carrier complexes, drug carriers, pharmaceutical formulations, methods of delivery drugs to an organism or tissue culture, methods of increasing the solubility of a substance, targeted carriers, drug delivery systems and implants are described. The compositions and methods of the invention include forming complexes having reversible associations between nucleotides and drugs. The compositions and methods of the invention can be employed to target drugs to cells, organisms or combinations of cells to treat and to study the underlying mechanisms of diseases, and to test drug candidates.

The present invention provides Lig-and-Drug Conjugates and Drug-Linker Compounds comprising a methylene carbamate unit. The invention provides inter alia, Ligand-Drug Conjugates, wherein the Ligand-Drug Conjugate is comprised of a Self-immolative Assembly Unit having a methylene carbamate unit for conjugation of a drug to a targeting ligand, methods of preparing and using them, and intermediates thereof. The Ligand-Drug Conjugates of the present invention are stable in circulation, yet capable of inflicting cell death once free drug is released from a Conjugate in the vicinity or within tumor cells.

The invention relates to a targeted drug-bearing ultrasonic microbubble comprising a lipide dimolecular layer outer shell, targeted polypeptide fixed at the outer side of the lipide dimolecular layer outer shell, a biological inert gas wrapped in the lipide dimolecular layer outer shell and medicament granules dispersed in the lipide dimolecular layer outer shell. The targeted polypeptide is a polypeptide or protein derivative containing an amino acid sequence CGNKRTRGC. By connecting the polypeptide or protein derivative containing a tumor targeted peptide sequence outside the lipide dimolecular layer outer shell, the obtained targeted drug-bearing ultrasonic microbubble can target the lymph vessels and the tumor cells of a tumor, can detect and diagnose the generation, the development and the curative effect on the tumor in real time through high-frequency ultrasonic imaging and can crush the microbubble through low-frequency ultrasound to release the medicament granules so as to achieve the aim of controllably and targetedly releasing the medicament, thereby having extremely important meanings to the prevention, diagnose and treatment of the tumor. In addition, the invention also relates to a preparation method of the targeted drug-bearing ultrasonic microbubble.

The present invention is directed to method and system for delivery of brain-targeted drugs to the cerebrospinal fluid via the perilymphatic fluid of the inner ear. The system utilizes the passage of cochlear aqueduct as a drug delivery route from the inner ear to the subarachnoid space of the brain. The delivery system includes an otological conduit which enables transfer of drugs from the auditory ear canal to the inner ear and a wearable dispenser for supplying drugs to the otological conduit. The drug composition comprises a suspension of solid lipid nanoparticles (SLN) which facilitate delivery through the cochlear aqueduct. Employing aspects of present invention, a method and system for treating chronic pain is described.

The invention provides a preparation method and a functionalized design method of a novel magnetic nano-pore metal-organic framework core-shell material preparation, and an application of the material in heavy metal ion selective removing and targeted drug loading. With a layered self-assembly method, the magnetic core-shell material with a magnetic material as a core and a nano-pore metal-organic framework as a shell is prepared, wherein the thickness of the nano-pore metal-organic framework shell layer can be effectively regulated through changing self-assembly conditions. The invention also provides a method for carrying out thiol functional design upon the magnetic nano-pore metal-organic framework material, and a method for carrying out organic and / or inorganic surface modification upon the surface of the nano-pore metal-organic framework magnetic core-shell material. The nano-pore metal-organic framework magnetic core-shell material provided by the invention can be used as an absorption material and a catalytic material, a heavy metal ion selective absorption and separation material, and a targeted drug loading carrier.

The present invention relates to the methods of treating endocrine-regulated cancers, including hormone resistant cancers, for example. More specifically, the present invention relates to a method of increasing the sensitivity of hormone resistant cancers to hormonal therapeutic agents. In particular embodiments, the present invention concerns delivery of a histone deacetylase inhibitor and a hormone targeted drug to an individual with cancer. In specific embodiments, the histone deacetylase inhibitor and the hormone targeted drug act synergistically to treat the cancer, including by overcoming resistance to a cancer therapy.

The invention discloses a preparation method for gold magnetic composite nanometer particles. Firstly, magnetic nanometer particles of Fe3O4 are prepared by using a chemical co-precipitation method, the surface of the magnetic particles are modified by a silane coupling agent, then with the modified nanometer particles of Fe3O4 as seeds and oil amine as a reduction agent, gold ions are reduced to metallic gold on the surface of the magnetic nanometer particles in an ultrasonic condition, then the nanometer particles are prepared. The nanometer particles have the advantages of good dispersion, strong magnetic response and having double bonds that can lead to polymerization reaction on the surface of the particles. The nanometer particles have the diameter of 30 to 50nm and saturation magnetization of 6.8 to 17.6 emu per gram, thus showing super paramagnetism. The nanometer particles not only have magnetic response function, but also can carry out polymerization reaction with a plurality of functional monomers, thus having wide application prospect in a plurality of fields, targeted drug control and release, hyperthermia, isolation of protein and enzyme, etc.

The invention relates to a controlled-release colon targeting drug adminitration preparation. The forms of the preparation are colon site-specific coated tablets or colon targeting pellets. The preparation consists of a tablet core or pellet core, an isolating layer and a controlled-release coating layer, wherein the controlled-release coating layer comprises an internal coating layer and an external coating layer. By adopting the multilayer coating technology, enteric soluble acrylic resin water dispersion and osmotic acrylic resin water dispersion are used as main coating materials for carrying out coating, thereby obtaining the controlled-release colon targeting drug adminitration preparation. The preparation of the invention enables drugs to be released at a constant rate at a colon section, realizes accurate site-specific drug release, increases the concentration of the drugs at some parts of positions with pathological changes, is beneficial to treating ulcerative colitis and carcinoma of colon, avoids the stimulation of the drugs on stomaches and small intestines, achieves the goal of colon site-specific drug release, enhances the targeting site-specific curative effect on colon diseases and reduces the toxic and side effect. Compared with the common oral preparations, under the condition of the same drug adminitration dosage, the preparation of the invention can enhance the curative effect and reduce the incidence rate of untoward reactions. Compared with the enemas or the rectal suppositories, the preparation has the advantages of uniform drug distribution in the colon and good patient compliance.

The invention discloses an aptamer and a new use of derivative thereof. The new use provided by the invention is application of aptamer and the derivative thereof in preparation of target drugs. The invention further protects the target drugs obtained by coupling the drugs with the aptamer or the derivative thereof. The invention has the advantages of screening and preparing specific aptamer or derivative thereof under the condition of not knowing the molecular transformation of the target cell surface related to the disease, and can simultaneously obtain multiple aptamers or derivatives thereof of molecular related to the cell surface cell; the specificity of the obtained aptamer or derivative thereof is strongly combined with the disease cell; the aptamer or the derivative thereof can be chemically synthesized in large scale and can be easily connected with the drug molecules and has low cost; the molecular weight of the aptamer or the derivative thereof is relatively small without immunologic competence and toxicity; the aptamer or the derivative thereof has good stability; and the formed target drugs are stable. The invention has very high application value.

The invention discloses a hollow microsphere with superparamagetism Fe3O4 nanocrystallines and a preparation method thereof. The hollow microsphere takes a silica shell as a casing, the thickness of the silica shell is 10-50nm, and the silica shell contains Fe3O4 nanocrystallines which contains hydrophobicity. The preparation method is as follows: dispersing the hydrophobic Fe3O4 nanocrystallines in an organic solution of silica precursor Si(OR)4 and hydrophobic high molecular by adopting a precipitating-phase separating method; adding water solution containing an surfactant; embedding the Fe3O4 nanocrystallines and the Si(OR)4 to form a compound microsphere by using the quick precipitation of the high molecular; adding ammonia water to catalyze the Si(OR)4 for hydrolytie polycondensation to form a SiO2 shell on the surface of the microsphere; and removing the high molecular by dissolving by a solvent. The hollow microsphere in the invention has superparamagetism, and has wide application prospect in the biomedical field like targeted drug carriers and the like.

The invention discloses a graphene / hyaluronic acid assembly taking cyclodextrin as a medium. The graphene / hyaluronic acid assembly is a nano supermolecule assembly synthesized based on beta-cyclodextrin-modified graphene and adamantine-modified hyaluronic acid, wherein graphene is modified by beta-cyclodextrin; by virtue of strong host-guest interaction between beta-cyclodextrin and adamantine, graphene and hyaluronic acid are combined together to form the supermolecule assembly. The graphene / hyaluronic acid assembly has the advantages that the supermolecule assembly greatly improves stability and biocompatibility of the cyclodextrin-modified graphene under physiological conditions; by utilizing targeted recognition action of hyaluronic acid on tumor cells, the supermolecule assembly can selectively kill the cancer cells, and has anti-cancer activity higher than that of pure drug camptothecin; the targeted drug transmission system is simple in preparation process, easy to implement and low in material cost, and has potential application prospect in clinic treatment of cancers.

The invention provides miRNA signatures and methods of making and using thereof. MiRNA signatures determine the responsiveness of HER2 expressing breast tumors to anti-HER2 treatment, such as the targeted drug therapy trastuzumab.